Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis.

Nicholson, Steve; Gooden, Calvin S. R.; Hird, V.; Maraveyas, Anthony; Mason, P R; Lambert, H. E.; Meares, Charles; Epenetos, Agamemnon A.

doi:10.3892/or.5.1.223

Cited by 39 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the advantages of targetted radionuclide therapy is that Auger electron, alpha particle, and beta particle emitters are effective therapeutic particles as they can localize the delivery of cytotoxic ionizing radiation [18]. By linking the emitters to biological agents, localized treatment can be achieved because of the high affinity of some elements for some organs and organ systems.…”

Section: Advantages and Disadvantages Of Targetted Radionuclide Therapymentioning

confidence: 99%

A brief review of targetted radionuclide therapies

Al-Rowaily¹,

Dondi²,

MarcoChinol³

et al. 2017

Pak J Nucl Med

View full text Add to dashboard Cite

Section: Advantages and Disadvantages Of Targetted Radionuclide Therapymentioning

confidence: 99%

A brief review of targetted radionuclide therapies

Al-Rowaily¹,

Dondi²,

MarcoChinol³

et al. 2017

Pak J Nucl Med

View full text Add to dashboard Cite

“…To date, 15 different antibodies have been used directed against 5 different tumor-associated antigens and one antiangiogenesis antigen (VEGF). Of the 44 clinical trials, 23 trials studied immunotherapy with unconjugated Mab (27,, five trials studied vaccination with Mabs (58-62), while 16 trials studied RIT (63)(64)(65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78). Two of the RIT trials used a combination of cytotoxic chemotherapy and RIT (64,71).…”

Section: Clinical Trialsmentioning

confidence: 99%

“…A combination of unconjugated Mabs combined with cytotoxic chemotherapy administration was assessed in four trials (43,47,53,57). Because of the high propensity to stay confined to the peritoneal cavity until very late in the course of the disease, many trials on radiolabeled Mab in ovarian cancer patients used the ip route for administration (19/44) (38,41,44,50,51,63,64,(66)(67)(68)(69)(70)(71)(73)(74)(75)(76)(77)(78). In 20 studies the Mab was administered iv (36,37,39,40,42,43,45-49,52-55,57,60,65,72,79), two studies injected im (59,61), while 2 other studies used both iv and ip routes of administration Table I.…”

Section: Clinical Trialsmentioning

confidence: 99%

“…Furthermore, radiolabeled ip HMFG1 induced an immune response resulting in proliferation of T-cells and the production of Ab2 and Ab3 (106-109). Nicholson et al (74) reported that the survival of 25 ovarian cancer patients in CCR who received 90 Y-HMFG1 (18 mCi) was prolonged compared to matched historical controls with a 5-year survival of respectively 70 vs. 32%. The same conclusions were drawn by Epenetos et al (67) who found a survival rate of 78% after >10 years of follow-up in 21 ovarian cancer patients in CCR who had received a single injection of 25 mg ip 90 Y-HMFG1 (12-32 mCi) (67).…”

Section: Muc1mentioning

confidence: 99%

See 1 more Smart Citation

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Massuger¹,

Boerman²,

Thomas³

et al. 2008

Int J Oncol

View full text Add to dashboard Cite

Abstract.The prognosis for patients with ovarian cancer is still poor and more effective therapeutic modalities are needed. (Radio)immunotherapy using monoclonal antibodies (Mabs) could be one of these approaches. Here, we review the status of (radio)immunotherapy using Mabs for the treatment of ovarian cancer. The Pubmed database was searched for clinical trials investigating the effect of (radio)immunotherapy in ovarian cancer published until October 1, 2007. Keywords for the search were: ovarian cancer, monoclonal antibodies, CA 125, gp38, HER2, HMFG, MUC1, TAG 72 and VEGF. A total of 44 trials on immunotherapy with unconjugated Mabs, Mab vaccination and (radio)immunotherapy directed towards the antigens CA 125, gp38, HER2, MUC1, TAG 72 or VEGF in patients with ovarian cancer were found, reviewed and discussed. Out of these trials, 23 studied immunotherapy with unconjugated Mabs, 5 vaccination with Mabs and 16 trials studied (radio)immunotherapy. The lack of large randomized prospective trials with Mabs directed to tumor-associated antigens expressed on ovarian cancer cells preclude any firm conclusion on the potential of Mabs use in the treatment of ovarian cancer. Oregovomab, directed against CA 125, and bevacizumab, targeting VEGF, are two unconjugated Mabs closest to clinical introduction for the treatment of ovarian cancer. Vaccination with Mab ACA 125 seems promising but these findings need to be confirmed in controlled randomized trials. Sole RIT should be investigated with the appropriate radionuclide and a Mab with high affinity for the specific tumor-associated antigen in the appropriate patient group to determine whether it may have a therapeutic effect. Additionally, appending (radio)immunotherapy with anti-TAG 72 or anti-MUC1 to other treatment strategies such as chemotherapy could also be a strategy worthwhile investigating. The potential of Mabs to complement current treatment paradigms, is encouraging and may bring a significant improvement to the overall therapeutic outcomes currently being achieved in ovarian cancer. IntroductionOvarian cancer is the fourth leading cause of cancer-related death in women, and accounts for the highest mortality rate of all gynecological malignancies (1). Its poor prognosis is mainly the result of the clinically occult nature of this disease. The peritoneal cavity in which the ovaries are localized provides a perfect environment for undisturbed subclinical growth. Furthermore, early detection is difficult because of the general asymptomatic presentation of the disease (2). In the majority (68%) of the patients, ovarian cancer is diagnosed with at least extensive abdominal spread (3). Standard treatment for advanced stage ovarian cancer is tumor debulking surgery and adjuvant chemotherapy. Although most ovarian cancers are sensitive to platinumbased chemotherapy, the prognosis remains poor. The 5-year INTERNATIONAL JOURNAL OF ONCOLOGY 32: 1145-1157 The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (Review) Abbreviations: ADCC, anti...

show abstract

“…В отличие от большинства солидных опухолей у пациентов с данной локализацией отмечался удовлетвори-тельный ответ на проведение РИТ, в том числе [8,34,35]. Изучается возможность проведения интра-перитонеальной радиоиммунотерапии, что объ-ясняется, прежде всего, диссеминированным и микроскопическим характером перитонеальных метастазов, которые трудно поддаются хирурги-ческому лечению, а использование РИТ позволит локально воздействовать минимальной дозой радиации на радиочувствительные органы.…”

unclassified